Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EBITDA (2022 - 2025)

Historic EBITDA for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to -$2.2 million.

  • bioAffinity Technologies' EBITDA fell 1628.51% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.2 million, marking a year-over-year decrease of 2657.63%. This contributed to the annual value of -$8.8 million for FY2024, which is 1357.79% down from last year.
  • As of Q3 2025, bioAffinity Technologies' EBITDA stood at -$2.2 million, which was down 1628.51% from -$2.5 million recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' EBITDA ranged from a high of -$684119.0 in Q2 2022 and a low of -$2.9 million during Q4 2024
  • Over the past 4 years, bioAffinity Technologies' median EBITDA value was -$1.9 million (recorded in 2024), while the average stood at -$1.9 million.
  • As far as peak fluctuations go, bioAffinity Technologies' EBITDA plummeted by 15687.78% in 2023, and later surged by 1404.89% in 2024.
  • Over the past 4 years, bioAffinity Technologies' EBITDA (Quarter) stood at -$1.6 million in 2022, then plummeted by 34.62% to -$2.2 million in 2023, then plummeted by 33.44% to -$2.9 million in 2024, then increased by 22.57% to -$2.2 million in 2025.
  • Its last three reported values are -$2.2 million in Q3 2025, -$2.5 million for Q2 2025, and -$2.6 million during Q1 2025.